10-Q: Twist Bioscience Reports 32% Revenue Growth in Q1 2024, Driven by NGS Tools and Gene Sales

Twist Bioscience saw a 32% increase in revenue year-over-year in the first quarter of fiscal year 2024, primarily driven by growth in NGS tools, synthetic genes, and DNA libraries.

Summary

• Twist Bioscience reported a 32% increase in revenue, reaching $71.5 million for the quarter ended December 31, 2023, compared to $54.2 million for the same period in 2022.
• The company's net loss was $43.0 million, slightly higher than the $41.8 million loss in the prior year's quarter.
• Revenue growth was primarily driven by a $15.1 million increase in NGS tools revenue, a $3.6 million increase in synthetic genes revenue, and a $1.1 million increase in DNA libraries revenue.
• The number of genes shipped increased by 28%, from 134,000 in Q1 2023 to 171,000 in Q1 2024.
• The company's operating expenses totaled $118.5 million, compared to $98.9 million in the same quarter of the previous year.
• As of December 31, 2023, Twist Bioscience had $266.3 million in cash and cash equivalents and $44.9 million in short-term investments.
• The company had an accumulated deficit of $1,076.2 million as of December 31, 2023.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While revenue growth is strong and the company has a solid cash position, the ongoing losses and material weakness in internal controls are concerning. The sentiment is cautiously optimistic.

Positives

• The company demonstrated strong revenue growth across multiple product lines, particularly in NGS tools and synthetic genes.
• The increase in gene shipments indicates growing demand for Twist Bioscience's products.
• The company maintains a solid cash position with over $311 million in cash and short-term investments.
• The company has a diverse customer base across various industries, including industrial chemicals/materials, academic research, healthcare, and food/agriculture.

Negatives

• The company continues to operate at a loss, with a net loss of $43.0 million for the quarter.
• Operating expenses increased to $118.5 million, which is higher than the $98.9 million in the same quarter of the previous year.
• Antibody discovery revenue decreased by $2.9 million due to a reduction in orders.
• The company has an accumulated deficit of $1,076.2 million, indicating ongoing losses since its inception.

Risks

• The company's manufacturing operations are primarily dependent on the Wilsonville facility, and any disruptions there could impact product supply.
• The company is exposed to risks from natural disasters, public health crises, and other events that could damage facilities or disrupt operations.
• The company relies on third-party carriers for product delivery, which could lead to delays and customer dissatisfaction.
• The company's ability to protect its intellectual property is uncertain, and patent oppositions could impact its rights.
• The company has identified a material weakness in internal control over financial reporting, which could lead to misstatements in financial reports.

Future Outlook

The company's ability to achieve profitability depends on the success of existing products, the development and commercialization of new products, and leveraging its investment in the Wilsonville manufacturing facility. The company also plans to expand in international markets and develop new applications for synthetic DNA, such as digital data storage.

Management Comments

• Management believes that the company's cash and cash equivalents and short-term investments of $311.1 million will be sufficient to fund operations for at least one year from the issuance of these consolidated financial statements.
• Management stated that the company is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products.
• Management noted that the company has built a scalable commercial platform that enables it to reach a diverse customer base in a variety of industries.

Industry Context

The company's growth in NGS tools and synthetic genes aligns with the broader trend of increasing demand for synthetic biology and genomics solutions in various industries. The company's focus on expanding its manufacturing capabilities and developing new applications for synthetic DNA positions it to capitalize on these trends.

Comparison to Industry Standards

• Twist Bioscience's 32% revenue growth is strong compared to some of its peers in the synthetic biology space, although direct comparisons are difficult due to varying business models and product focuses.
• Companies like Ginkgo Bioworks and Amyris also operate in the synthetic biology sector, but their financial results and growth trajectories differ significantly from Twist Bioscience.
• The company's focus on DNA synthesis and NGS tools places it in competition with companies like Illumina and Thermo Fisher Scientific, which are larger and more established players in the genomics market.
• Twist Bioscience's gene synthesis capabilities are comparable to those of companies like GenScript, but Twist's silicon-based platform offers a unique approach to manufacturing DNA.
• The company's continued losses are not uncommon for growth-stage biotech companies, but the magnitude of the accumulated deficit is a concern that needs to be addressed.

Management Changes

Legal Proceedings

• The company is involved in a securities class action lawsuit and a shareholder derivative suit, both related to allegations made in a report issued by Scorpion Capital.
• The company has filed a motion to dismiss the amended complaint in the securities class action lawsuit, with a hearing scheduled for April 18, 2024.

Related Party Transactions

• The company purchased raw materials from a related party in the amount of $1.3 million and $2.1 million during the three months ended December 31, 2023 and 2022, respectively.
• The company had revenues from the related party in the amount of $2.3 million and $0.2 million during the three months ended December 31, 2023 and 2022, respectively.

Stakeholder Impact

• Shareholders are impacted by the company's revenue growth and ongoing losses, as well as the legal proceedings and material weakness in internal controls.
• Employees are impacted by the company's restructuring plan and changes in personnel costs.
• Customers are impacted by the company's product offerings and delivery capabilities.
• Suppliers are impacted by the company's purchasing activities and related party transactions.
• Creditors are impacted by the company's financial performance and liquidity.

Next Steps

• The company will continue to focus on expanding its manufacturing capabilities, particularly at the Wilsonville facility.
• The company will continue to develop and commercialize new products in the synthetic biology, biologic drug, and data storage industries.
• The company will continue to address the material weakness in internal control over financial reporting.
• The company will continue to monitor and manage risks related to manufacturing, intellectual property, and market conditions.

Key Dates

Keywords

DNA synthesis, synthetic biology, genomics, NGS tools, synthetic genes, DNA libraries, antibody discovery, revenue growth, financial results, biotechnology